Skip to content

Clinical trials

Observational Carcinoma, Ovarian Epithelial trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Carcinoma, Ovarian Epithelial Phase: Observational Country / region: United States Clear all

34 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20021
20031
20041
20054
20062
20075
20084
20093
20102
20171
20191
20201
20211
20221
20231
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed14
Terminated10
Recruiting4
Withdrawn3
Unknown status2
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Vanderbilt-Ingram Cancer Center4
M.D. Anderson Cancer Center2
Mayo Clinic2
Northwestern University2
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)1
Baylor Research Institute1
Case Comprehensive Cancer Center1
City of Hope Medical Center1
Guardant Health, Inc.1
Gynecologic Oncology Group1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Carcinoma, Ovarian Epithelial34
Ovarian Neoplasms23
Breast Neoplasms10
Fallopian Tube Neoplasms9
Carcinoma, Non-Small-Cell Lung7
Burkitt Lymphoma6
Endometrial Neoplasms6
Leukemia, Lymphocytic, Chronic, B-Cell6
Lymphoma, B-Cell, Marginal Zone6
Lymphoma, Follicular6

Trials

Showing 1 to 25 of 34. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.